Table 2 Main variables characteristics
Age (ranges) | 40–60 | 77 (12.6 %) |
61–70 | 262 (43 %) | |
>70 | 265 (43.5 %) | |
Unknown | 5 (0.8 %) | |
Performance score | 0 | 290 (47.6 %) |
1 | 72 (11.8 %) | |
2 | 1 (0.2 %) | |
3 | 1 (0.2 %) | |
Unknown | 245 (40.2 %) | |
Risk (D’Amico) | Low | 140 (23 %) |
Intermediate | 195 (32 %) | |
High | 272 (44.7 %) | |
Unknown | 2 (0.3 %) | |
Treatment | RT | 85 (14 %) |
RT + HT | 348 (57.1 %) | |
Cx + RT | 87 (14.3 %) | |
BQ | 88 (14.4 %) | |
Unknown | 1 (0.2 %) | |
RT technique | 3D | 369 (60.6 %) |
IGRT | 140 (23.0 %) | |
BQ | 88 (14.4 %) | |
Unknown | 12 (2.0 %) | |
RT dose (Gy) | <76 | 96 (15.8 %) |
76 | 367 (60.3 %) | |
>76 | 56 (9.2 %) | |
Unknown | 2 (0.3 %) | |
BQ | 88 (14.4 %) | |
Volumea | Prostate | 331 (63.5 %) |
+ Vesicles | 119 (22.8 %) | |
+ Lymph nodes | 67 (12.9 %) | |
Unknown | 4 (0.8 %) | |
Toxicityb | GI 0 | 218 (41.8 %) |
1 | 175 (33.6 %) | |
2 | 86 (16.5 %) | |
3 | 2 (0.4 %) | |
Unknown | 40 (7.7 %) | |
GU 0 | 432 (82.9 %) | |
1 | 38 (7.3 %) | |
2 | 14 (2.7 %) | |
3 | 1 (0.2 %) | |
Unknown | 36 (6.9 %) |